Buventol Easyhaler (salbutamol dry-powder inhaler) / Orion Corp - LARVOL DELTA

Impact of Pre-Actuation Shaking on the Aerosolization Performance of Easyhaler® Salbutamol Dry Powder Inhaler. (PubMed, Pharm Res) - "Pre-actuation shaking substantially influences the aerosolization performance of Easyhaler® Salbutamol. At least three vertical shakes are required to achieve optimal fine particle delivery and reduce throat deposition. These findings highlight the importance of proper patient instruction on device handling. Further studies should assess whether similar effects occur with other Easyhaler® formulations."

Journal

Inspiratory Profiles Through Easyhaler Dry Powder Inhaler During Acute Bronchoconstriction. (PubMed, J Aerosol Med Pulm Drug Deliv) - " This study was conducted as part of a parallel-group clinical trial assessing use of Salbutamol Easyhaler, Budesonide-formoterol Easyhaler and salbutamol pMDI with spacer during a methacholine challenge (MC) test...Aside from two subjects using EH-mono during bronchoconstriction, all subjects were able to generate PIF ≥ 30 L/min. During an acute obstructive event, the vast majority of patients have no difficulty in achieving sufficient PIF, inhalation acceleration, and volume after PIF when using an Easyhaler DPI."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Effect of non-spherical shape of dry powder aerosol drugs on their airway deposition distribution. (PubMed, Int J Pharm) - "Aerosol particles of Bretaris® Genuair®, Buventol® Easyhaler® and Trelegy® Ellipta® were collected on the stages of a Next Generation Impactor after their emission from the dry powder inhalers...Although there was some inter-drug difference in terms of shape factors, the values were quite close to unity (usually between 1.02 and 1.06), except for the fiber-shaped particles representing a minority in the composition of Trelegy® Ellipta®, which could be characterized by shape factors of around 1.6. The results of computer simulations of deposition distribution indicate that neglecting the irregular shape does not lead to a major distortion of the simulation results unless fiber-shaped particles are also present after the formulation."

Journal

Non-inferior relief of bronchoconstriction with salbutamol via Easyhaler dry powder inhaler compared to pressurised metered dose inhaler with spacer (ERS 2024) - "The differences in FEV1 between Budesonide-formoterol EH and salbutamol pMDI with spacer were -0.163 L (-0.225) after the first and -0.092 L (-0.131) after the last dose. Conclusions The study confirms non-inferiority of Salbutamol EH to Ventoline Evohaler with spacer in relieving acute bronchoconstriction, making EH a sustainable and safe reliever for MC test and asthma attacks."

Asthma • Immunology • Respiratory Diseases

Salbutamol Easyhaler provides non-inferior relief of methacholine induced bronchoconstriction in comparison to Ventoline Evohaler with spacer: a randomized trial. (PubMed, Respir Med) - "The study confirms non-inferiority of Salbutamol Easyhaler to Ventoline Evohaler with spacer in relieving acute bronchoconstriction, making Easyhaler a sustainable and safe reliever for MC test and supports its use during asthma attacks."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

EASYRELIEF: Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing (clinicaltrials.gov) - P4 | N=180 | Completed | Sponsor: Orion Corporation, Orion Pharma | Recruiting ➔ Completed

Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

EASYRELIEF: Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing (clinicaltrials.gov) - P4 | N=180 | Recruiting | Sponsor: Orion Corporation, Orion Pharma | Trial completion date: Sep 2022 ➔ May 2023 | Trial primary completion date: Sep 2022 ➔ May 2023

Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

EASYRELIEF: Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing (clinicaltrials.gov) - P4 | N=180 | Recruiting | Sponsor: Orion Corporation, Orion Pharma | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

EASYRELIEF: Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing (clinicaltrials.gov) - P4; N=180; Not yet recruiting; Sponsor: Orion Corporation, Orion Pharma

Clinical • New P4 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Inspiratory flow parameters of Easyhaler and Diskus Inhalers (SALIF) (clinicaltrials.gov) - P=NA, N=200; Not yet open

New trial • Asthma